We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Scancell Holdings Plc | LSE:SCLP | London | Ordinary Share | GB00B63D3314 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.63 | -6.60% | 8.92 | 9.10 | 9.50 | 9.55 | 9.30 | 9.55 | 186,473 | 16:35:13 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 5.27M | -11.94M | -0.0129 | -7.21 | 86.29M |
Date | Subject | Author | Discuss |
---|---|---|---|
12/4/2018 20:27 | If you can't construct a reasoned argument there is always obscenities - the last resort of the intellectually challenged. | gazza | |
12/4/2018 17:11 | Tosh, apols for saying much the same as your 14913, posted mine and only saw it after! ATB Mikethebike.. is your handle in deference to M.Hailwood esq? :-) | oldnotwise | |
12/4/2018 17:08 | J777J.. as you say, "If it does a all pan out and they do have a cure for multiple cancers forget £1 a share,try £20 a share." At least you accept we all HOPE for the outcome you mention (as do you with your use of the word "IF") so by definition you have answered why we don't say "cure" yet, and yes, when we do get a deal, that'll be the time to find out what we're worth. I'm sure we've all got ideas, but it's a bit premature for "Valuations".... Time and Trial Results will have significant impacts on any final deal together with any new discoveries or platforms. Should the entire company be sold rather than selling/licensing/me It's for those reasons I continue to implore, "patience". Looks like we agree really, so great to have a discussion rather than a slanging match! :-) AIMO ATB | oldnotwise | |
12/4/2018 17:03 | J7 Improve your sentence construction "If it does a all pan out and ..... Same old ignorant ramping stuff as you have been spouting on FUM Don't ruin this thread as well ! mtb4 | mikethebike4 | |
12/4/2018 17:01 | j7, I agree.. in fact, even £20 would seem pretty modest. IMHO. But the biggest word in your statement is " IF ",. Get rid of the IF , and the sky is the limit, We're someway off that at the moment though I'm afraid. Many hills to climb, and many risks to be over come. Have a good evening. | tosh 123 | |
12/4/2018 16:52 | Oh and one more thing.If it does a all pan out and they do have a cure for multiple cancers forget £1 a share,try £20 a share.Happy hunting | j777j | |
12/4/2018 16:52 | j7, if it had completed the regulatory testing process and was now available to everyone, then I would agree, however, neither of those two aspects have happened, or indeed are likely to happen, for at least 2 years. Also, as ONW rightly points out, if, as you are advocating, this is a proven cure, then why oh why has not one large bio come and snapped us up ? All the big players have plenty of cash in their respective coffers, as well a very real need to replenish their pipelines, so, if, as you say, the cure has been proven, why are we still under funded and looking for more cash to keep the lights on within the next couple of months ? Anyway, I think that your point has been discussed. Lets just agree to disagree. The share price and market Cap sort of gives you a large clue as to who's prognosis is more accurate. | tosh 123 | |
12/4/2018 16:45 | Say whatever you want but they are in talks with many parties.They have the best oncologists in the world on board.Leading cancer charities.Patient advocate groups.It is simply a matter of time. | j777j | |
12/4/2018 16:40 | J777J Obviously it's proven to anyone who's benefitted from the trials.... BUT we're talking here about the Financial side of the company. Consequently since we've seen extraordinary results from the trials so far it hasn't prompted any Pharma to say the same thing (IE Buying the company and the "Cure"). Since we are still waiting, in answer to your 14905, I'll say again, "NOT YET". Simple as that. AIMO ATB | oldnotwise | |
12/4/2018 16:37 | Those are the facts on the ground.Now of course there will be larger trials,but I repeat most of those cancer patients that have received treatment are alive,well,leading normal lives.It's the elephant in the room. | j777j | |
12/4/2018 16:34 | To those patients alive and well and leading normal lives after 6 years it is proven.This is reality. | j777j | |
12/4/2018 16:25 | When you have multiple patients cancer free after nearly 6 years and leading normal lives,when do you start using the cure word? | j777j | |
12/4/2018 16:20 | I think you'll find that we are all in, that's not the issue, we all have the belief / hope, that at some point, value will be realised, we just have more realistic expectations and appraisals of the risk factors and timings than others, all of which I might add, have been proven to be absolutely well founded. A multiple cure is worth billions, ONCE it has been proven and is available , NOT when its still in development. Scancell still need a lot of help, a lot of money, and a lot of fortune. All these factors should not be dismissed. | tosh 123 | |
12/4/2018 16:07 | People tend to invest years ahead of time. What is the value of a co with multiple cancer cures? A lot more than £47 million. I'm in shouldn't you be? ;-) | j777j | |
12/4/2018 15:44 | j7, I think the word " premature " is wildly understating the claims of many, for many years. They were, and still are, totally unrealistic, and based off blind faith rather than common sense. Without getting drawn into lengthy posts about the ludicrous claims of many on the other channel, lets just say that fairy tales rule over there. Please don't try to drag this BB down to their level. | tosh 123 | |
12/4/2018 15:08 | oh no - not J7 | mikethebike4 | |
12/4/2018 14:38 | Well Lozan, certainly not UNBALANCED hehe.. I think once we (as investors) realise that the company has a pair of platforms that appear to be better than many/most already out there, we simply have to sit back and wait. The market will eventually determine what the majority think the IP is ultimately worth, and that will probably be some way off. So conjecture rules, but I'm hopeful of a rerate in the weeks/ months ahead, but being prepared to wait patiently for what we all hope Scancell will be. Hard "values" being put on shares ATM are IMO simply premature guesswork which to me are irrelevant ATM. There's a long way to go so as I mentioned earlier it's pleasant to arrive here and see some cautious optimism rather than overblown self aggrandissment. AIMO ATB | oldnotwise | |
12/4/2018 14:33 | This is so going to get taken over.Crazy not to at least have a few shares in the bottom drawer.The £1 a share club were just premature,not neccessarily wrong.Tiny UK co with a potential cure for multiple cancers. | j777j | |
12/4/2018 14:26 | O N W et al - " beginning to enjoy the posts here..." . Might that be due to folks finally seeing- in no small part to Tosh - that posts here are now far more = BALANCED ??? | the real lozan | |
12/4/2018 14:13 | Hope noone minds me saying, but rather beginning to enjoy the posts here... at least we all agree, hang on in the HOPE that it all works out! I must admit to being optimistic that the Fully documented grant of Patent will assist any Major who's either "been in touch" or eyeing developments from the sidelines in making some sort of (perhaps minor) decision which might avail SCLP of some cash. :-) That's my optimistic line (to maintain some degree of perspective in SCLP's future! There's certainly no guarantees in the BioTech "Game" AIMO GLA | oldnotwise | |
12/4/2018 13:32 | Tosh - agree, it would be fantastic but I don't believe either that it's merely a case of the Patent coming through. I posted the link as a commentary on the way 2018 looks to be shaping up for the sector in general, nothing more. Fwiw - I agree with rHatton . . . . we know from the Calculus presentation document that the BioNTech research collaboration started in (earnest ?) Q1 2018 and that the completion of the "initial" evaluation of Modi specific TCR's is due H1 2019. P 10/58 Re your comments on RG - that old chestnut. I don't remember him saying anything recently to indicate anything different. As you know RG had previously admitted to learning to be more cautious & in his last Proactive presentation (when filling in for Holloway) he was very open in refusing to commit to a specific timeframe. Seems lesson learnt. Some though (myself included) remain intrigued as to the nature of his "left field" remark in that presentation. Good to hear you are holding on tight to your shares. We don't agree on everything but that's cool - might be boring otherwise. | gooosed | |
12/4/2018 12:37 | Good to see you here sir. One would hope that if there is some kind of gentlemens / formal agreement with BioNtech, that the BOD would announce it, if only to assist the long suffering shareholders to retain their holdings, or at least feel more comfortable that their loyalty will be rewarded at some stage. At present, we are still very much under pressure as funds will be needed soon, and in the absence of any other formal direction, the market will always take the worst case scenario eg ;- another raising at a distressed price. Lets see what happens though. | tosh 123 | |
12/4/2018 12:07 | Likewise Tosh. I joined you guys a few weeks back on IMM, hopefully not much longer to wait with that! Who knows maybe BioNtech will jump in earlier if they like what they see. I think on the presentation it said H1 2019 for the TCR study to complete. | rhatton |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions